GWLL GOLDENWELL BIOTECH INC.
Distress ·
Goldenwell said it could not compile its financial information in time and expects to file by August 19, 2025. Its notice also says an annual report has not been filed, and its latest filed balance sheet is small.
We have not published a story on GOLDENWELL BIOTECH INC. yet. When there is news, it will appear here.
Goldenwell Biotech Inc. was incorporated on August 20, 2019, and has no subsidiaries. Its business offices are in Solon, Ohio, where the company says it only receives mail and does not conduct operations. The company holds exclusive license agreements, one with Australian Trefoil Health Technologies Pty Ltd, which is controlled by a director of the company, and one with Ji Lin JZY Biotech Inc., which covers the technology the company uses in its products. The company describes five products, which are polypeptide freeze-dried powders, and states that for each it has completed marketing analysis, research and development, and production stages. Its first described product, JI MAI, is a bovine cardiac vascular active peptide made from healthy and fresh bovine cardiac vascular tissues. The company says production needs no specialized equipment and that its workforce needs no specialized education or experience. Its audited financial summary shows cash and cash equivalents of $26,775 as of December 31, 2025, against total liabilities of $379,833.
| Product or program | What it is | Stage |
|---|---|---|
| JI MAI | Freeze-dried bovine cardiac vascular active peptide product | research, development and production stages completed |
GOLDENWELL BIOTECH INC. trades under the ticker GWLL on OTC.
GOLDENWELL BIOTECH INC. is listed on OTC.
The SEC Central Index Key (CIK) for GOLDENWELL BIOTECH INC. is 1800373. Its filings are on SEC EDGAR.
99,000,000 shares as of 2026-08-11, per the cover page of its 10-Q filed 2026-08-14.
Our directory records GOLDENWELL BIOTECH INC. under United States.
Our directory classifies GOLDENWELL BIOTECH INC. as: Mixed biopharma / other operations. This is a directory classification, not a description of the pipeline.
The ISIN recorded for GOLDENWELL BIOTECH INC. is US38138N1046.
aibio.space lists GOLDENWELL BIOTECH INC. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as NV.
Goldenwell Biotech Inc. was incorporated on August 20, 2019, and has no subsidiaries. Its business offices are in Solon, Ohio, where the company says it only receives mail and does not conduct operations.
JI MAI: Freeze-dried bovine cardiac vascular active peptide product Stage: research, development and production stages completed.
$55 for the fiscal year ended Dec 31, 2025, as reported to the SEC.
GOLDENWELL BIOTECH INC. reported a net loss of $296,471 for the fiscal year ended Dec 31, 2025, and used $22,629 of cash in operations, per its annual report to the SEC.
$11,143 in cash at Jun 30, 2026, per its 10-Q.
Our latest story on GOLDENWELL BIOTECH INC., dated Aug 14, 2025: "Goldenwell Biotech files late notice for June quarter report". Goldenwell said it could not compile its financial information in time and expects to file by August 19, 2025. Its notice also says an annual report has not been filed, and its latest filed balance sheet is small. Source.
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Said earlier financial statements should no longer be relied on. SEC Form 8-K (Items 4.02,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio